Skip to main content
ALLR
NASDAQ Life Sciences

Allarity Swaps $3M of Streeterville Debt for Senior Preferred, Gives Lender 33% of ATM Proceeds

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.87
Mkt Cap
$14.001M
52W Low
$0.769
52W High
$1.84
52W Position info
13% above low
Off High info
53% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ALLR is trading near its 52-week low of $0.769 (13% above the low).

Summary

Allarity exchanged $3 million of its Streeterville note for 3,000 senior Series B preferred shares paying 9%, and in return Streeterville gets 33% of any future ATM net proceeds plus veto rights over new debt, equity and asset sales. No cash was raised.


Key Events · Financing and Capital Events · ALLR

  • Debt Swapped for Senior Preferred

    Allarity partitioned $3,000,000 from its $10,930,000 Streeterville A-1 Note and exchanged it for 3,000 Series B preferred shares with a $1,050 stated value, cutting the note balance to $7,930,000. The exchange closed November 16, 2026, with no cash proceeds.

  • 9% Preferred Sits Ahead of Common

    The Series B accrues a 9% annual return compounded daily (15% after default), ranks senior to common in liquidation, and is not convertible into common stock. The 3,000 shares carry an aggregate stated value of $3,150,000.

  • Lender Takes 33% of ATM Proceeds

    The Side Letter lets Allarity sell stock under an ATM only if it pays Streeterville 33% of weekly net proceeds, applied to preferred redemption or note repayment at Streeterville's election. Streeterville can revoke the consent at any time, and a missed payment is an event of default.

  • Covenants Restrict Financing and Sales

    While Series B is outstanding, Allarity cannot make restricted debt or equity issuances, pledge assets, do a reverse split outside a Nasdaq deficiency cure, or enter a Fundamental Transaction without majority holder consent.


Analysis · ALLR · Life Sciences

Allarity retired $3 million of the $10.93 million Streeterville note by issuing 3,000 Series B preferred shares with a $1,050 stated value — $3.15 million in senior claims that sit ahead of common stock in liquidation and pay a 9% annual return, payable in cash or more preferred. No cash changed hands, so this is a balance-sheet restructuring rather than new money. The real cost is in the Side Letter: Streeterville consented to future ATM sales only if it receives 33% of the weekly net proceeds, applied to preferred redemption or note repayment at its election, and it can revoke that consent at any time. For a company that disclosed substantial doubt about its ability to continue as a going concern in its November 13 10-Q, that is a heavy toll on the only equity financing channel it has left. The covenants also block new debt or equity issuance, asset pledges, reverse splits outside a Nasdaq deficiency cure, and any Fundamental Transaction without Streeterville's consent — effectively giving one lender a veto over most financing and sale paths. The concurrent Phase 2 stenoparib trial expansion is a genuine clinical positive, but it does not change the capital structure math.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALLR was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14M. The 52-week trading range was $0.77 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALLR - Latest Insights

ALLR
Nov 13, 2026, 8:07 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.900 info
Change: -$0.050 (-5%) info
Market Cap: $14.001M info
ALLR
Nov 13, 2026, 8:05 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.950
Real-time Price: $0.900 info
Change: -$0.050 (-5%) info
Market Cap: $14.001M info
ALLR
Nov 02, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8415
Real-time Price: $0.900 info
Change: +$0.0585 (+7%) info
Market Cap: $14.001M info
ALLR
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.870
Real-time Price: $0.900 info
Change: +$0.030 (+3%) info
Market Cap: $14.001M info
ALLR
Sep 14, 2026, 12:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.900 info
Change: -$0.310 (-26%) info
Market Cap: $14.001M info